

Effect of undercarboxylated osteocalcin on experimentally induced diabetic cardiomyopathy in male rats and its possible mechanisms of action.

Thesis

Submitted in fulfillment of the requirements

For The MD of Science in

Physiology

By

Sarah Mahmoud Gamal Abd-El Aziz

Assistant lecturer of Physiology

Faculty of Medicine – Cairo University

Under supervision of

Prof. Dr. Maha Mohamed Gamal El-Din

Professor of Physiology

Head of Physiology Department

Faculty of Medicine – Cairo University

Prof. Dr. Heba Mohamed Shawky

Professor of Physiology

Faculty of Medicine – Cairo University

Prof. Dr. Laila Ahmad Rashed

Professor of Biochemistry

Faculty of Medicine – Cairo University

Dr. Nermeen Bakr Sadek

Lecturer of Physiology

Faculty of Medicine – Cairo University

Cairo University

2015



صدق الله العظيم،،

"وَعَلَّمَكَ مَا لَمْ تَكُن تَعْلَمُ وَكَانَ فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا"

(سورة النساء - من آية 113)

ACKNOWLEDGEMENT

All praise and thanks are due to ALLAH, The Most Merciful.

*I would like to express my sincere thanks from the heart and deep appreciation to **Prof. Dr. Maha Mohamed Gamal**, Professor of Physiology, the Head of Physiology department Faculty of Medicine, Cairo University, for her great guidance and generous help throughout the course of this study and supervision of the work, as well as her unlimited encouragement, advice and stimulating criticism.*

*I 'm also grateful to **Dr. Heba Shawky**, Professor of Physiology, Faculty of Medicine, Cairo University, **Dr. Nermeen Bakr**, lecturer of Physiology, Faculty of Medicine, Cairo University and **Prof. Dr. Laila Ahmed Rashed**, Professor of Biochemistry, Faculty of Medicine, Cairo University, for their help, kind advice and guidance throughout the work as well as sharing in the supervision.*

I would also like to express my deep appreciation to all the staff members of Physiology Department particularly my dear colleagues for their great support.

Last but not least, special deep appreciation from the heart is given to my dear family, especially my parents, my husband and my mother in law. I dedicate this work to them for their generous support and sincere encouragement.

Abstract

Background: Diabetes mellitus (DM) is a major epidemic of this century. Epidemiological studies indicate that more than 70% of diabetes mellitus (DM) patients die of cardiovascular disease (CVD). Damage to the diabetic myocardium in the absence of hypertension and coronary artery is termed diabetic cardiomyopathy (DCM). Osteocalcin (OC) is a bone matrix protein that undergoes post translational carboxylation at 3 sites by carboxylase enzyme. Full carboxylation is essential for retaining OC in bone bound to hydroxyapatite. The undercarboxylated (ucOC) form is released in the blood as a hormone with several actions on energy and glucose metabolism. It stimulates insulin secretion and enhances insulin sensitivity at least in part via stimulating adiponectin. Osteocalcin was found to be related to lower cardiovascular risk in human adults. Use of vitamin K antagonists (eg. Warfarin) can block the activity of carboxylase enzyme, increasing the undercarboxylated portion of OC. The present work was designed to study the possible prophylactic and therapeutic effects of elevated plasma ucOC on diabetic cardiomyopathy in type II DM and associated risk factors, and to investigate the role of possible underlying mechanisms. The possibility of a direct action for osteocalcin on the heart was also studied.

Methods: 56 adult male albino rats were divided into 6 groups (n=8/group):_control group (further divided to control A and B), diabetic group, diabetic warfarin prophylaxis group, DCM untreated group, DCM warfarin treated group and normal warfarin treated group, for these groups, isolated heart function was assessed by measuring LV developed pressure, $\Delta P/\Delta T$ and $-\Delta P/\Delta T$ using powerlab data acquisition system aided by Langendorff heart perfusion apparatus. Blood samples were collected for measuring Fasting blood glucose and serum insulin as well as glycosylated hemoglobin and HOMA IR was calculated, besides, lipid profile was investigated by measuring serum triglycerides, VLDL and HDL for evaluation of risk factors in addition to serum ucOC and adiponectin. Cardiac tissue samples were taken to investigate malonaldehyde (MDA) content, acyl co-A dehydrogenase gene expression, TNF α , Bax/BCL2 ratio, VEGF gene expression and

SERCA gene expression. Besides, the gene expression of OC receptor (GPRC6A) was assessed in the cardiac tissue.

Results: According to the results of the current study, ucOC elevation via antagonizing the carboxylase enzyme using warfarin was accompanied by increased serum adiponectin and upregulated myocardial OC receptor in addition to favorable metabolic effects enhancing insulin secretion, lowering blood glucose and improving insulin sensitivity and lipid profile. Increased ucOC showed a protective effect against the development of DCM when administered as prophylaxis, and although not fully reversed, the condition of the myocardium was significantly improved when ucOC was elevated even after the settlement of DCM as a treatment. These favorable effects of ucOC were proved by functional assessment of isolated heart, which showed improvement in LV developed pressure systolic $\Delta P/\Delta T$, and diastolic - $\Delta P/\Delta T$. Further investigating the underlying mechanisms emphasized that effect, showing decreased cardiac MDA content, acyl co-A dehydrogenase gene expression, TNF α and Bax/BCL2 ratio, together with increased VEGF gene expression and SERCA gene expression.

Conclusions: The present study added an evidence for the protective effect of ucOC against diabetic drawbacks through improving plasma glucose level, insulin secretion and sensitivity as well as ameliorating dyslipidemia. These metabolic benefits are considered through both direct action of ucOC on the pancreas, and indirectly through adiponectin. ucOC was further proved to have a beneficial effect on diabetic heart, protecting it from the development DCM and even improving the state of the heart that has already developed DCM. This might be related to the ucOC systemic effects or to local effects through antagonizing the oxidative stress, anti apoptotic and/or anti inflammatory factors. The associated upregulated cardiac OC receptor expression raised the possibility of a direct action of ucOC on diabetic heart, a point that needs further studies. Applicability in humans also needs further study.

Key words: DCM, Warfarin, ucOC, Adiponectin, MDA, BAX/BCL2, SERCA.

LIST OF CONTENTS

INTRODUCTION AND AIM OF WORK	1
REVIEW OF LITERATURE	3
Osteocalcin	3
Diabetic cardiomyopathy	33
MATERIALS AND METHODS	71
RESULTS	116
DISCUSSION.....	177
SUMMARY AND CONCLUSION.....	197
REFERENCES	203

LIST OF TABLES

- ❖ **Table (1)** Cholesterol standard series preparation.....92
- ❖ **Table (2)** Sequence of the primers used for real-time PCR108
- ❖ **Table (3)** Comparison between mean \pm SD of Fasting Serum insulin, Fasting blood glucose, HOMA IR, Glycosylated hemoglobin %, Serum triglycerides, VLDL cholesterol and HDL in control group (1A) (n=8) and Diabetic group (2)(n=8).....118
- ❖ **Table (4)** Comparison between mean \pm SD of serum adiponectin, ucOC and GPRC6A gene expression in cardiac tissue in control group (1A) (n=8) and Diabetic group (2)(n=8):.....119
- ❖ **Table (5)** Comparison between mean \pm SD of LV developed pressure and ΔP / ΔT in control group (1A) (n=8) and Diabetic group (2)(n=8).....120
- ❖ **Table (6)** Comparison between mean \pm SD of MDA content, Acyl co-A dehydrogenase gene expression, TNF α , VEGF gene expression SERCA gene expression, BAX/BCL2 ratio in control group (1A) (n=8) and Diabetic group (2)(n=8).....121
- ❖ **Table (7)** Comparison between mean \pm SD of Fasting Serum insulin, Fasting blood glucose, HOMA IR, Glycosylated hemoglobin %, Serum triglycerides, VLDL cholesterol and HDL in control group (1B) (n=8) and DCM untreated group (4) (n=8)122

- ❖ **Table (8)** Comparison between mean \pm SD of serum adiponectin, ucOC and GPRC6A gene expression in cardiac tissue in control group (1B) (n=8) and DCM untreated group (4) (n=8).....123

- ❖ **Table (9)** Comparison between mean \pm SD of LV developed pressure and $\Delta P / \Delta T$ in control group (1B) (n=8) and DCM untreated group (4) (n=8).....124

- ❖ **Table (10)** Comparison between mean \pm SD of MDA content, Acyl co-A dehydrogenase gene expression, TNF α , VEGF gene expression SERCA gene expression, BAX/BCL2 ratio in control group (1B) (n=8) and DCM untreated group (4) (n=8).....125

- ❖ **Table (11)** Comparison between mean \pm SD of Fasting Serum insulin, Fasting blood glucose, HOMA IR, Glycosylated hemoglobin %, Serum triglycerides, VLDL cholesterol and HDL in DCM untreated 18w group (4) (n=8) and Diabetic group (2)(n=8).....126

- ❖ **Table (12)** Comparison between mean \pm SD of serum adiponectin, ucOC and GPRC6A gene expression in cardiac tissue in DCM untreated 18w group (4) (n=8) and Diabetic group (2)(n=8).....127

- ❖ **Table (13)** Comparison between mean \pm SD of LV developed pressure and $\Delta P / \Delta T$ in DCM untreated 18w group (4) (n=8) and Diabetic group (2)(n=8).....128

- ❖ **Table (14)** Comparison between mean \pm SD of studied MDA content, Acyl co-A dehydrogenase gene expression, TNF α , VEGF gene expression SERCA gene expression, BAX/BCL2 ratio in DCM untreated 18w group (4) (n=8) and Diabetic group (2)(n=8).....129

- ❖ **Table (15)** Comparison between mean \pm SD of Fasting Serum insulin, Fasting blood glucose, HOMA IR, Glycosylated hemoglobin %, Serum triglycerides, VLDL cholesterol and HDL, in control group (1A) (n=8) and normal warfarin treated group (6) (n=8).....130

- ❖ **Table (16)** Comparison between mean \pm SD of serum adiponectin, ucOC and GPRC6A gene expression in cardiac tissue in control group (1A) (n=8) and normal warfarin treated group (6) (n=8).....131

- ❖ **Table (17)** Comparison between mean \pm SD of LV developed pressure and $\Delta P / \Delta T$ in control group (1A) (n=8) and normal warfarin treated group (6) (n=8).....132

- ❖ **Table (18)** Comparison between mean \pm SD of MDA content, Acyl co-A dehydrogenase gene expression, TNF α , VEGF gene expression SERCA gene expression, BAX/BCL2 ratio in control group (1A) (n=8) and normal warfarin treated group (6) (n=8).....133

- ❖ **Table (19)** Mean \pm SD of Fasting Serum insulin, Fasting blood glucose, HOMA IR, Glycosylated hemoglobin %, Serum triglycerides, VLDL cholesterol and HDL in warfarin prophylaxis group (3) (n=8) in comparison to control group (1A) (n=8) and Diabetic group (2) (n=8).....134

- ❖ **Table (20)** Mean \pm SD of serum adiponectin, ucOC and GPRC6A gene expression in cardiac tissue in warfarin prophylaxis group (3) (n=8) in comparison to control group (1A) (n=8) and Diabetic group(2) (n=8).....136

- ❖ **Table (21)** Mean \pm SD of LV developed pressure and $\Delta P / \Delta T$ in warfarin prophylaxis group (3) (n=8) in comparison to control group (1A) (n=8) and diabetic group(2) (n=8).....137

- ❖ **Table (22)** Mean \pm SD of MDA content, Acyl co-A dehydrogenase gene expression, TNF α , VEGF gene expression SERCA gene expression, BAX/BCL2 ratio in warfarin prophylaxis group (3) (n=8) in comparison to control group (1A) (n=8) and diabetic group(2) (n=8).....138

- ❖ **Table (23)** Mean \pm SD of Fasting Serum insulin, Fasting blood glucose, HOMA IR, Glycosylated hemoglobin %, Serum triglycerides, VLDL cholesterol and HDL in warfarin treated group (5) (n=8) in comparison to control group (1B) (n=8) and DCM untreated group(4) (n=8).....139

- ❖ **Table (24)** Mean \pm SD of serum adiponectin, ucOC and GPRC6A gene expression in cardiac tissue in in warfarin treated group (5) (n=8) in comparison to control group (1B) (n=8) and DCM untreated group(4) (n=8).....140

- ❖ **Table (25)** Mean \pm SD of LV developed pressure and $\Delta P / \Delta T$ in warfarin treated group (5) (n=8) in comparison to control group (1B) (n=8) and DCM untreated group(4) (n=8).....141

- ❖ **Table (26)** Mean \pm SD of MDA content, Acyl co-A dehydrogenase gene expression, TNF α , VEGF gene expression SERCA gene expression, BAX/BCL2 ratio in DCM warfarin treated group (5) in comparison to control group (1B) (n=8) and DCM untreated group(4) (n=8).....142
- ❖ **Table (27)** Cumulative table : Comparison between mean \pm SD of all studied parameters in all groups(n=8).....143
- ❖ **Table (28):** correlation between serum ucOC and Serum adiponectin, cardiac tissue MDA content, Acyl coA dehydrogenase, TNF α , SERCA gene expression, VEGF gene expression and BAX/BCL2 ratio in all studied groups.....171
- ❖ **Table (29):** Correlation between serum adiponectin level and OC receptor (GPRC6A) gene expression in cardiac tissue among all studied groups...175

LIST OF FIGURES

❖ <u>Figure (1)</u> Mature Ocn molecule (fully carboxylated) with Gla residues at 17, 21 and 24 positions.	5
❖ <u>Figure (2)</u> Intact Ocn molecule and potential fragments	8
❖ <u>Figure (3)</u> Suggested loop between bone and pancreatic beta cells.	9
❖ <u>Figure (4)</u> Proposed regulation of Esp expression and Ocn carboxylation in mice	13
❖ <u>Figure (5)</u> A diagram of the osteocalcin molecule calcium binding sites	20
❖ <u>Figure (6)</u> Osteocalcin, leptin, and adiponectin interact to influence insulin resistance.....	24
❖ <u>Figure (7)</u> The pathophysiological substrate of DCM.....	40
❖ <u>Figure (8)</u> Potential contributors to the development of diabetic cardiomyopathy	43
❖ <u>Figure (9)</u> Overview of the proposed impact of increased AR pathway flux in diabetic cardiovascular tissue	44
❖ <u>Figure (10)</u> Schematic depiction of the multiple potential mechanisms that have been implicated in the pathophysiology of DCM.....	64
❖ <u>Figure (11)</u> Schematic presentation of Experimental protocol	74
❖ <u>Figure (12)</u> Langendorff heart perfusion apparatus	78

❖ <u>Figure (13)</u> Calibrator Diluent RD5-26 dilution series.....	101
❖ <u>Figure (14)</u> Calibrator Diluent RD5-17 dilution series.....	113
❖ <u>Figure (15)</u> Fasting blood glucose(Mmol/L) in all studied groups	145
❖ <u>Figure (16)</u> Fasting serum insulin(μ U/L) in all studied group.....	146
❖ <u>Figure (17)</u> HOMA IR in all studied groups	147
❖ <u>Figure (18)</u> Glycosylated hemoglobin in all studied groups	148
❖ <u>Figure (19)</u> serum triglycerides in all studied groups.....	149
❖ <u>Figure (20)</u> VLDL cholesterol in all studied groups	150
❖ <u>Figure (21)</u> HDL in all studied groups	151
❖ <u>Figure (22)</u> Serum ucOC in all studied groups	152
❖ <u>Figure (23)</u> OC receptor (GPRC6A) gene expression in all studied groups.....	153
❖ <u>Figure (24)</u> Serum adiponectin in all studied groups	154
❖ <u>Figure (25)</u> Malone dialdehyde (MDA) content in all studied groups ...	155
❖ <u>Figure (26)</u> Acyl coA dehydrogenase gene expression in all studied groups	156
❖ <u>Figure (27)</u> TNF α in all studied groups	157
❖ <u>Figure (28)</u> VEGF gene expression in all studied groups	158
❖ <u>Figure (29)</u> SERCA gene expression in all studied groups	159
❖ <u>Figure (30)</u> BAX/BCL2 ratio in all studied groups	160
❖ <u>Figure (31)</u> LV developed pressure (mmHg) in all studied groups	161

❖ Figure (32) $\Delta P / \Delta T$ (mmHg/s.) in all studied groups	162
❖ Figure (33) $-\Delta P / \Delta T$ (mmHg/s.) in all studied groups	163
❖ Figure (34) Sample of lab chart of cardiac function in control (1A) group.....	164
❖ Figure (35) Sample of lab chart of cardiac function in control (1B) group.....	165
❖ Figure (36) Sample of lab chart of cardiac function in Diabetic (10w) group (2).....	166
❖ Figure (37) Sample of lab chart of cardiac function in diabetic warfarin prophylaxis group (3).....	167
❖ Figure (38) Sample of lab chart of cardiac function in DCM untreated (18w) group (4).....	168
❖ Figure (39) Sample of lab chart of cardiac function in DCM warfarin treated group (5).....	169
❖ Figure (40) Sample of lab chart of cardiac function in normal warfarin treated group (6).....	170
❖ Figure (41) Positive correlation between serum ucOC level and serum adiponectin.....	172
❖ Figure (42) Negative correlation between serum ucOC level and MDA content in cardiac tissue	172
❖ Figure (43) Negative correlation between serum ucOC level and acyl co-A dehydrogenase in cardiac tissue	173
❖ Figure (44) Negative correlation between serum ucOC level and TNF α in cardiac tissue	173
❖ Figure (45) Positive correlation between serum ucOC level and SERCA gene expression in cardiac tissue	174

❖ <u>Figure (46)</u> Positive correlation between serum ucOC level and VEGF gene expression in cardiac tissue	174
❖ <u>Figure (47)</u> Negative correlation between serum ucOC level and BAX/BCL2 ratio in cardiac tissue	175
❖ <u>Figure (48)</u> Positive correlation between serum adiponectin level and OC receptor (GPRC6A) gene expression in cardiac tissue	176